有晶体眼后房型人工晶体植入术治疗超高度近视的临床疗效及安全性探究  

Study on clinical effect and safety of implantable collamer lens implantation in treatment of super high myopia

作　　者：李旭青[1] 蔡晓峰[1] 庹瑶[1] 陈康[1] 

机构地区：[1]解放军第324医院眼科,重庆400020

出　　处：《检验医学与临床》2015年第16期2369-2370,2374,共3页Laboratory Medicine and Clinic

摘　　要：目的观察有晶体眼后房型人工晶体（ICL）植入术治疗超高度近视的临床疗效及安全性。方法回顾性分析2010年1月至2014年1月该院眼科收治的ICL植入治疗的超高度近视患者45例共计83眼。患者均于手术前、后检查裸眼视力（UCVA）、最佳矫正视力（BCVA）、眼压、角膜内皮细胞计数、晶状体等变化及并发症发生情况。结果结果术前患者UCVA为0.01~0.05,术后6个月,88.0%UCVA≥0.3,32.5%UCVA≥0.6;85.5%BCVA≥0.3,39.8%BCVA≥0.6。术前患者眼压为（13.1±0.51）mm Hg,术后为（13.7±0.68）mm Hg,与术前比较,差异无统计学意义（P〉0.05）;术前患者角膜内皮细胞计数为（3 201±238）/mm2,术后为（3 142±254）/mm2,治疗前后计数差异无统计学意义（P〉0.05）。结论 ICL植入治疗超高度近视临床疗效确切,手术安全可靠,值得临床推广和进一步深入研究。Objective To observe the effects and safety of implantable collamer lens（ICL） implantation in the treatment of super high myopia. Methods The clinical data of 45 patients （83 eyes） with super high myopia treated by the LCL implantation in our hospital from Jan 2010 to Jan 2014 were retrospectively analyzed. The uncorrected visual acuity（UCVA）, best corrected visual acuity（BCVA）, intraocular pressure, corneal endothelial cells count and lens were checked before operation and in 6 months after surgery. The occurrence situation of complications was ob- served. Results UCVA was 0. 01-0.05 pre operatively. The UCVA was improved to 0. 3 in 88.0% and 0. 6 in 32.5%. BCVA was improved to 0.3 in 85.5% and 0.6 in 39.8% after 6 months. The pre-intraocular pressure and post-intraocular pressure were（ 13.1 ± 0.51 ） mm Hg and （ 13.7± 0.68） mm Hg respectively. The corneal endothelial cells counts before and after operation were （3 201 ± 238）/mm^2 and（3 142 ± 254）/mm^2 respectively, showing no sta- tistically significant differences between before and after operation（P〉0.05）. Conclusion The ICL implantation has exact effect and safety for treating super high myopia and deserves to be clinically promoted and deeply studied.

关 键 词：超高度近视 晶体植入 后房 

分 类 号：R776.1[医药卫生—眼科]